302 related articles for article (PubMed ID: 16110821)
21. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
Hamza NS; Ghannoum MA; Lazarus HM
Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
[TBL] [Abstract][Full Text] [Related]
22. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
23. Antifungal agents in hematopoietic stem cell transplantation.
Parameswaran GI; Segal BH; Almyroudis NG
Curr Pharm Des; 2008; 14(20):2011-21. PubMed ID: 18691111
[TBL] [Abstract][Full Text] [Related]
24. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
25. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.
Döring M; Blume O; Haufe S; Hartmann U; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2014 Apr; 33(4):629-38. PubMed ID: 24173819
[TBL] [Abstract][Full Text] [Related]
26. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
27. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
30. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
31. Management of invasive mycoses in hematology patients: current approaches.
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
[TBL] [Abstract][Full Text] [Related]
32. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.
Wirk B; Wingard JR
Mycopathologia; 2009 Dec; 168(6):299-311. PubMed ID: 19247798
[TBL] [Abstract][Full Text] [Related]
33. Novel preventative strategies against invasive aspergillosis.
Mantadakis E; Samonis G
Med Mycol; 2006 Sep; 44(Supplement_1):S327-S332. PubMed ID: 30408925
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
35. Aspergillosis prophylaxis and treatment for pediatric HSCT patients: environmental and pharmacologic options.
Doyle SC
J Pediatr Oncol Nurs; 2008; 25(5):240-6. PubMed ID: 18660459
[TBL] [Abstract][Full Text] [Related]
36. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.
Maschmeyer G; Haas A; Cornely OA
Drugs; 2007; 67(11):1567-601. PubMed ID: 17661528
[TBL] [Abstract][Full Text] [Related]
37. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
Lehrnbecher T; Fisher BT; Phillips B; Beauchemin M; Carlesse F; Castagnola E; Duong N; Dupuis LL; Fioravantti V; Groll AH; Haeusler GM; Roilides E; Science M; Steinbach WJ; Tissing W; Warris A; Patel P; Robinson PD; Sung L
J Clin Oncol; 2020 Sep; 38(27):3205-3216. PubMed ID: 32459599
[TBL] [Abstract][Full Text] [Related]
38. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
39. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.
Maschmeyer G
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i27-30. PubMed ID: 19372178
[TBL] [Abstract][Full Text] [Related]
40. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
